• Timothy J Atkinson, Pisansky Andrew J B AJB, Katie L Miller, and R Jason Yong.
• axialHealthcare, Inc, Cummins Station, 209 S 10th Ave S #332, Nashville, TN 37203. Email: tatkinson@axialhealthcare.com.
• Am J Manag Care. 2019 Mar 1; 25 (3): e88-e97.

ObjectivesThis study sought to formulate a consolidation of guidelines representing best practices related to office-based opioid treatment (OBOT) of opioid use disorder (OUD) using buprenorphine. It also demonstrates how a set of evidence-based guidelines may be linked with claims data to leverage analytic techniques that drive cost-effective, positive health outcomes.Study DesignLiterature review of US and international guidelines for OBOT using buprenorphine for OUD.MethodsThe study conducted a review of currently available US and several international guidelines from 2009 to 2018 published on OUD and the use of buprenorphine in OBOT. Guidelines were consolidated based on common elements. The process of correlating common elements with available commercial and state Medicaid claims data is described, including which elements are amenable to analysis along with relative complexity.ResultsSeven guidelines met inclusion criteria and are presented as 3 tables, organized by clinical themes and phase of care related to OBOT use of buprenorphine for OUD. Themes included establishing care, monitoring treatment stability and engagement, and nonpharmacologic treatment to improve outcomes. Areas of agreement and divergence between guidelines are highlighted. Specific components are identified as they relate to metrics of interest to public and private payers.ConclusionsAmong US and international guidelines for treatment of OUD, common themes are readily identified and may indicate agreement in regard to interventions. Linking pharmacy and medical billing claims data to evidence-supported best practices provides public and private payers the ability to track individual patients, facilitate high-quality care, and monitor outcomes.

19 keywords...

hide…